Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 13 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Alcohol Abuse
Interventions: Alcohol, Saline; Drug
Lead sponsor: Mark Fillmore; Other
Eligibility: 21 Years to 29 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Asthma
Interventions: Mepolizumab IV, Mepolizumab SC, IV Placebo, SC Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • Newport Beach, California • Riverside, California + 17 more

Conditions: Drug Dependence
Interventions: 2-4 of the drugs listed below; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Patients at Risk for Melanoma
Interventions: N-acetylcysteine, Placebo arm; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Autism Spectrum Disorders
Interventions: Intranasal Oxytocin, Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Major Depressive Disorder
Interventions: ketamine, IV Saline, ECT, Muscle Relaxant, Anesthetic Agents; Drug · Other · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nerve Block, Pain, Postoperative, Pelvic Floor Disorders, Pelvic Organ Prolapse, Pudendal Neuralgia, Surgery
Interventions: Pudendal block; Procedure
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more

Conditions: Myocarditis Acute
Interventions: Methylprednisolone, saline solution; Drug
Lead sponsor: Niguarda Hospital; Other
Eligibility: 18 Years to 69 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 4
States / cities: San Diego, California • Houston, Texas • Charlottesville, Virginia + 1 more

Conditions: Cerebral Palsy
Interventions: umbilical cord blood (hUCB) cells, Saline Infusion (Placebo), bone marrow derived mononuclear cells (BMMNCs); Biological · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 10 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Bupivacaine, patient-reported pain scores, saline; Drug · Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: New-onset Type 1 Diabetes Mellitus
Interventions: Alefacept, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 35 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 12 more

Conditions: Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty, Ankle Fusion
Interventions: Mepivacaine, Perifemoral Injection of Local Anesthetic, Saline; Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Rotavirus Infections
Interventions: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo; Biological · Other
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cystic Fibrosis, CF, Lung Infection, Pseudomonas Aeruginosa
Interventions: Aztreonam for Inhalation (AI), Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 20
States / cities: Los Angeles, California • Orange, California • San Diego, California + 17 more

Conditions: Uterine Atony, Uterine Atony With Hemorrhage, Postpartum Hemorrhage, Cesarean Section Complications
Interventions: Calcium chloride, Saline placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pacifica, California

Conditions: Cough
Interventions: Citric Acid; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Herpes Simplex Type 2
Interventions: HerpV and QS-21, Placebo; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Portland, Oregon • Houston, Texas • Seattle, Washington

Conditions: COVID-19
Interventions: Interferon beta-1a, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more

Conditions: Labor Pain
Interventions: Ephedrine, Placebo; Drug
Lead sponsor: Sharp HealthCare; Other
Eligibility: Female only
Enrollment: 710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 1,345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more

Conditions: Acute Pain
Interventions: IV Acetaminophen, IV Control; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 1 Day to 2 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 22
States / cities: Birmingham, Alabama • Orange, California • San Diego, California + 19 more

Search by objective public record fields.

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

Sex Differences in Risk for Alcohol Abuse

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

Drug Discrimination in Methadone-Maintained Humans Study 3

Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo

Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

Pudendal Nerve Block in Vaginal Surgery

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

MYTHS - MYocarditis THerapy With Steroids

Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).

Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

Inducing Remission in Type 1 Diabetes With Alefacept

Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension

CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery

Esophageal Motility in Reflux Induced Cough

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Prophylactic Ephedrine and Combined Spinal Epidurals for Labor

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients